We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Test Stratifies Patients with Bladder Cancer Symptoms

By LabMedica International staff writers
Posted on 01 Jun 2015
Print article
Image: Cxbladder kit, for the noninvasive laboratory test for the detection of bladder cancer (Photo courtesy of Peter Wren-Hilton).
Image: Cxbladder kit, for the noninvasive laboratory test for the detection of bladder cancer (Photo courtesy of Peter Wren-Hilton).
A urine-based molecular diagnostic combines clinical risk factors and gene expression biomarkers to accurately triage patients presenting with blood in their urine (hematuria) who have a low probability of urothelial cancer (UC or bladder cancer).

Hematuria can be symptomatic of UC and ruling out patients with benign causes of such bleeding during primary evaluation is challenging. Patients with hematuria must typically undergo a full urological workup to investigate the possibility of bladder cancer, with a corresponding increase in the overall clinical and financial burden of these patients on health care systems.

Urologists at Palmerston North Hospital (New Zealand) working with a commercial company collected data from 587 patients with macrohematuria. Expression of five genes in a voided urine sample (genotypic) and age, gender, frequency of macrohematuria and smoking history (phenotypic) was analyzed. To provide gene expression data, a single mid-stream urine sample was collected from participants using the Urine Sampling System. Multigene analysis of samples from all studies was carried out in accordance with the standard operating procedure, as is used for the commercially available multigenic test.

Both urine sampling system and the multigenic Cxbladder Triage test are products of Pacific Edge Ltd. (Dunedin, New Zealand). Cxbladder Triage is a novel molecular test that combines the power of the genomic biomarkers with extra phenotypic and clinical risk factors to accurately identify and remove patients with hematuria who have a low probability of bladder cancer, from needing to have a full-urological work-up. In total, samples from 587 patients were available for modelling comprising 72 UC-positive and 515 UC-negative samples. A combined genotypic-phenotypic model (G + P INDEX) was compared with genotypic (G INDEX) and phenotypic (P INDEX) models. Area under receiver operating characteristic curves (AUC) defined the performance of each INDEX.

The G + P INDEX offered a bias-corrected AUC of 0.86 compared with 0.61 and 0.83, for the P and G INDEXs respectively. When the test-negative rate was 0.4, the G + P INDEX (sensitivity = 0.95; negative predictive value (NPV) = 0.98) offered improved performance compared with the G INDEX (sensitivity = 0.86; NPV = 0.96). In all 80% of patients with microhematuria who did not have UC were correctly triaged out using the G + P INDEX, therefore not requiring a full urological work-up.

David Gregory Darling, Chief Executive Officer of Pacific Edge, said, “This study shows that Cxbladder Triage can accurately identify those patients who have a low probability of UC with a high level of sensitivity (95%) and high negative predictive value NPV (98%). The use of this test will enable physicians to evaluate those patients presenting with hematuria, and quickly and accurately remove those with a low probability of cancer, thereby reducing the number of individuals who require an expensive and invasive full urological workup. The use of Cxbladder Triage will also allow clinicians to make effective choices about the deployment of their skills and capabilities on the patients who need it most.” The study was published on March 27, 2015, in the journal BMC Urology.

Related Links:

Palmerston North Hospital 
Pacific Edge Ltd. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.